Cencora, Inc. (COR) Total Return CAGR:-3.81%(TTM)
Over the latest trailing 12-month period, Cencora, Inc. (COR)'s total return cagr is -3.81%. The comparable SPY value is +24.27%. Year-to-date total return is -16.27%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Cencora, Inc.'s Total Return CAGR averages 17.24% over 3 years and 19.86% over 5 years. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of Cencora, Inc.'s investment performance.
COR Total Return CAGR Chart
Cencora, Inc. (COR)
COR Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
COR Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 12698.13 | 10632.04 | -2066.09 | -16.27% | -16.27% |
| 2025 | 8382.41 | 12698.13 | +4315.72 | +51.49% | +51.49% |
| 2024 | 7594.36 | 8382.41 | +788.05 | +10.38% | +10.38% |
| 2023 | 6059.74 | 7594.36 | +1534.62 | +25.32% | +25.32% |
| 2022 | 4799.41 | 6059.74 | +1260.32 | +26.26% | +26.26% |
| 2021 | 3477.04 | 4799.41 | +1322.37 | +38.03% | +38.03% |
| 2020 | 2971.69 | 3477.04 | +505.35 | +17.01% | +17.01% |
| 2019 | 2409.00 | 2971.69 | +562.70 | +23.36% | +23.36% |
| 2018 | 2781.91 | 2409.00 | -372.91 | -13.40% | -13.40% |
| 2017 | 2236.87 | 2781.91 | +545.04 | +24.37% | +24.37% |
| 2016 | 2899.76 | 2236.87 | -662.89 | -22.86% | -22.86% |
| 2015 | 2449.55 | 2899.76 | +450.21 | +18.38% | +18.38% |
| 2014 | 1885.12 | 2449.55 | +564.44 | +29.94% | +29.94% |
| 2013 | 1140.03 | 1885.12 | +745.08 | +65.36% | +65.36% |
| 2012 | 966.53 | 1140.03 | +173.51 | +17.95% | +17.95% |
| 2011 | 876.15 | 966.53 | +90.37 | +10.31% | +10.31% |
| 2010 | 661.80 | 876.15 | +214.35 | +32.39% | +32.39% |
| 2009 | 447.41 | 661.80 | +214.39 | +47.92% | +47.92% |
| 2008 | 557.83 | 447.41 | -110.43 | -19.80% | -19.80% |
| 2007 | 556.45 | 557.83 | +1.38 | +0.25% | +0.25% |
| 2006 | 510.97 | 556.45 | +45.48 | +8.90% | +8.90% |
| 2005 | 361.49 | 510.97 | +149.49 | +41.35% | +41.35% |
| 2004 | 352.49 | 361.49 | +9.00 | +2.55% | +2.55% |
| 2003 | 333.48 | 352.49 | +19.00 | +5.70% | +5.70% |
| 2002 | 389.64 | 333.48 | -56.15 | -14.41% | -14.41% |
| 2001 | 309.56 | 389.64 | +80.08 | +25.87% | +25.87% |
| 2000 | 93.14 | 309.56 | +216.42 | +232.37% | +232.37% |
| 1999 | 199.26 | 93.14 | -106.13 | -53.26% | -53.26% |
| 1998 | 178.43 | 199.26 | +20.83 | +11.68% | +11.68% |
| 1997 | 147.79 | 178.43 | +30.64 | +20.73% | +20.73% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 10,632 | -10.1% | -2.9% |
| Q1 2026 | 11,830 | -7.7% | +18.3% |
| Q4 2025 | 12,822 | +14.3% | +52.9% |
| Q3 2025 | 11,216 | +2.4% | +34.0% |
| Q2 2025 | 10,951 | +9.5% | +29.3% |
| Q1 2025 | 10,003 | +19.3% | +11.2% |
| Q4 2024 | 8,384 | +0.1% | +12.1% |
| Q3 2024 | 8,372 | -1.1% | +22.7% |
| Q2 2024 | 8,467 | -5.9% | +23.9% |
| Q1 2024 | 8,998 | +20.3% | +53.9% |
| Q4 2023 | 7,479 | +9.7% | +21.0% |
| Q3 2023 | 6,821 | -0.2% | +37.2% |
| Q2 2023 | 6,836 | +17.0% | +26.7% |
| Q1 2023 | 5,845 | -5.4% | +6.5% |
| Q4 2022 | 6,180 | +24.3% | +28.8% |
| Q3 2022 | 4,971 | -7.9% | +15.6% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch